vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and ZIPRECRUITER, INC. (ZIP). Click either name above to swap in a different company.

ZIPRECRUITER, INC. is the larger business by last-quarter revenue ($111.7M vs $85.1M, roughly 1.3× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -0.7%, a 23.5% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 0.6%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $7.6M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -4.4%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

FDMT vs ZIP — Head-to-Head

Bigger by revenue
ZIP
ZIP
1.3× larger
ZIP
$111.7M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508899.4% gap
FDMT
8508900.0%
0.6%
ZIP
Higher net margin
FDMT
FDMT
23.5% more per $
FDMT
22.8%
-0.7%
ZIP
More free cash flow
FDMT
FDMT
$20.9M more FCF
FDMT
$28.5M
$7.6M
ZIP
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-4.4%
ZIP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FDMT
FDMT
ZIP
ZIP
Revenue
$85.1M
$111.7M
Net Profit
$19.4M
$-835.0K
Gross Margin
89.1%
Operating Margin
17.3%
3.6%
Net Margin
22.8%
-0.7%
Revenue YoY
8508900.0%
0.6%
Net Profit YoY
139.1%
92.3%
EPS (diluted)
$0.43
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
ZIP
ZIP
Q4 25
$85.1M
$111.7M
Q3 25
$90.0K
$115.0M
Q2 25
$15.0K
$112.2M
Q1 25
$14.0K
$110.1M
Q4 24
$1.0K
$111.0M
Q3 24
$3.0K
$117.1M
Q2 24
$5.0K
$123.7M
Q1 24
$28.0K
$122.2M
Net Profit
FDMT
FDMT
ZIP
ZIP
Q4 25
$19.4M
$-835.0K
Q3 25
$-56.9M
$-9.8M
Q2 25
$-54.7M
$-9.5M
Q1 25
$-48.0M
$-12.8M
Q4 24
$-10.8M
Q3 24
$-43.8M
$-2.6M
Q2 24
$-35.0M
$7.0M
Q1 24
$-32.4M
$-6.5M
Gross Margin
FDMT
FDMT
ZIP
ZIP
Q4 25
89.1%
Q3 25
89.1%
Q2 25
89.3%
Q1 25
89.4%
Q4 24
89.6%
Q3 24
89.4%
Q2 24
89.5%
Q1 24
89.1%
Operating Margin
FDMT
FDMT
ZIP
ZIP
Q4 25
17.3%
3.6%
Q3 25
-67983.3%
-4.4%
Q2 25
-396373.3%
-5.9%
Q1 25
-383007.1%
-10.6%
Q4 24
-3.6%
Q3 24
-1704400.0%
-2.8%
Q2 24
-849120.0%
7.6%
Q1 24
-136200.0%
-0.7%
Net Margin
FDMT
FDMT
ZIP
ZIP
Q4 25
22.8%
-0.7%
Q3 25
-63195.6%
-8.5%
Q2 25
-364386.7%
-8.5%
Q1 25
-342657.1%
-11.7%
Q4 24
-9.7%
Q3 24
-1461433.3%
-2.2%
Q2 24
-699060.0%
5.7%
Q1 24
-115717.9%
-5.3%
EPS (diluted)
FDMT
FDMT
ZIP
ZIP
Q4 25
$0.43
$-0.03
Q3 25
$-1.01
$-0.11
Q2 25
$-0.98
$-0.10
Q1 25
$-0.86
$-0.13
Q4 24
$-0.10
Q3 24
$-0.79
$-0.03
Q2 24
$-0.63
$0.07
Q1 24
$-0.66
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
ZIP
ZIP
Cash + ST InvestmentsLiquidity on hand
$402.7M
$188.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$505.7M
$-77.2M
Total Assets
$566.7M
$569.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
ZIP
ZIP
Q4 25
$402.7M
$188.0M
Q3 25
$305.1M
$211.8M
Q2 25
$293.2M
$203.5M
Q1 25
$321.4M
$221.1M
Q4 24
$424.9M
$218.4M
Q3 24
$501.9M
$225.6M
Q2 24
$541.9M
$271.7M
Q1 24
$525.9M
$282.5M
Stockholders' Equity
FDMT
FDMT
ZIP
ZIP
Q4 25
$505.7M
$-77.2M
Q3 25
$369.0M
$-76.1M
Q2 25
$420.9M
$-65.9M
Q1 25
$469.7M
$-11.3M
Q4 24
$510.6M
$13.4M
Q3 24
$552.9M
$13.6M
Q2 24
$588.3M
$24.4M
Q1 24
$600.6M
$12.7M
Total Assets
FDMT
FDMT
ZIP
ZIP
Q4 25
$566.7M
$569.7M
Q3 25
$424.0M
$573.6M
Q2 25
$473.6M
$592.4M
Q1 25
$515.7M
$629.4M
Q4 24
$560.4M
$664.1M
Q3 24
$604.0M
$652.0M
Q2 24
$620.1M
$665.3M
Q1 24
$629.9M
$662.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
ZIP
ZIP
Operating Cash FlowLast quarter
$28.6M
$7.7M
Free Cash FlowOCF − Capex
$28.5M
$7.6M
FCF MarginFCF / Revenue
33.5%
6.8%
Capex IntensityCapex / Revenue
0.1%
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M
$9.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
ZIP
ZIP
Q4 25
$28.6M
$7.7M
Q3 25
$-46.5M
$2.6M
Q2 25
$-43.4M
$10.5M
Q1 25
$-47.8M
$-9.9M
Q4 24
$-134.6M
$12.5M
Q3 24
$-29.4M
$9.3M
Q2 24
$-30.2M
$21.9M
Q1 24
$-29.1M
$2.0M
Free Cash Flow
FDMT
FDMT
ZIP
ZIP
Q4 25
$28.5M
$7.6M
Q3 25
$-46.6M
$2.2M
Q2 25
$-43.4M
$10.2M
Q1 25
$-48.4M
$-10.2M
Q4 24
$-138.4M
$12.0M
Q3 24
$-31.2M
$9.2M
Q2 24
$-30.6M
$21.7M
Q1 24
$-29.8M
$1.9M
FCF Margin
FDMT
FDMT
ZIP
ZIP
Q4 25
33.5%
6.8%
Q3 25
-51765.6%
1.9%
Q2 25
-289620.0%
9.1%
Q1 25
-345635.7%
-9.3%
Q4 24
-13837100.0%
10.8%
Q3 24
-1038966.7%
7.8%
Q2 24
-611840.0%
17.6%
Q1 24
-106421.4%
1.6%
Capex Intensity
FDMT
FDMT
ZIP
ZIP
Q4 25
0.1%
0.1%
Q3 25
101.1%
0.3%
Q2 25
440.0%
0.3%
Q1 25
4507.1%
0.3%
Q4 24
378600.0%
0.4%
Q3 24
59266.7%
0.2%
Q2 24
6980.0%
0.1%
Q1 24
2535.7%
0.1%
Cash Conversion
FDMT
FDMT
ZIP
ZIP
Q4 25
1.47×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
3.12×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FDMT
FDMT

Segment breakdown not available.

ZIP
ZIP

License$84.3M75%
Services$27.4M25%

Related Comparisons